Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Common Equity (2016 - 2025)

Historic Common Equity for Bio-Techne (TECH) over the last 16 years, with Q4 2025 value amounting to $2.0 billion.

  • Bio-Techne's Common Equity fell 324.77% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year decrease of 324.77%. This contributed to the annual value of $1.9 billion for FY2025, which is 725.24% down from last year.
  • Bio-Techne's Common Equity amounted to $2.0 billion in Q4 2025, which was down 324.77% from $2.0 billion recorded in Q3 2025.
  • Bio-Techne's 5-year Common Equity high stood at $2.1 billion for Q3 2024, and its period low was $1.5 billion during Q1 2021.
  • Its 5-year average for Common Equity is $1.9 billion, with a median of $1.9 billion in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 1987.77% in 2021, then tumbled by 808.15% in 2025.
  • Bio-Techne's Common Equity (Quarter) stood at $1.7 billion in 2021, then rose by 7.29% to $1.8 billion in 2022, then grew by 7.47% to $2.0 billion in 2023, then grew by 5.85% to $2.1 billion in 2024, then fell by 3.25% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q4 2025, $2.0 billion for Q3 2025, and $1.9 billion during Q2 2025.